Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2026-02-05 Notice of Dividend Amou…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding a 'Cash/In-kind Dividend Decision'. It details the dividend amount per share, dividend yield, total dividend amount, and the scheduled date for the general meeting of shareholders to approve these dividends. This falls directly under the definition of a dividend announcement.
2026-02-05 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by JW Pharmaceutical. It outlines the date, location, agenda items (such as financial statement approval, director appointments, and business purpose changes), and voting procedures. This document serves as the official notification and proxy solicitation material sent to shareholders to inform them of the upcoming meeting and the matters to be voted upon. According to the provided definitions, this fits the Proxy Solicitation & Information Statement (PSI) category.
2026-02-05 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend yield, the total dividend amount, and the scheduled date for the general meeting of shareholders to approve these payments. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2026-02-05 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 98% confidence The document is a regulatory filing from JW Pharmaceutical regarding the determination of a record date for cash/in-kind dividends. It specifies the record date (2026-04-01) and the purpose (confirming shareholders for dividends). Since it is a formal announcement of dividend-related record dates rather than the actual payment amount or a general regulatory notice, it falls under the category of dividend-related announcements.
2026-02-05 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from JW Pharmaceutical detailing the status and operational plan of their 'Compliance Program' (CP). It outlines past performance (2025 H2) and future plans (2026 H1) regarding internal governance, training, monitoring, and disciplinary actions. This type of disclosure is a standard regulatory announcement in the Korean market (KIND system) regarding corporate governance and compliance practices. Since it does not fit into specific categories like financial reports, M&A, or shareholder meetings, it is classified as a general regulatory filing.
2026-02-05 Korean
매출액또는손익구조30%(대규모법인15%)미만변경(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from JW Pharmaceutical regarding the 'Change in Sales or Profit/Loss Structure' (a common Korean regulatory disclosure requirement). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year 2025 compared to 2024. It explicitly states that these are preliminary figures subject to audit and shareholder approval. Since this is an initial announcement of financial results (key highlights) rather than a full annual report or a transcript, it falls under the Earnings Release category.
2026-02-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.